ZEO Signs Definitive Deal With Pluri; Pluri to Own 50% of ZEO at Closing
ZEOX sits 71% above its 52-week low of $0.842 on elevated volume (6.5× avg).
Summary
ZEO signed a definitive agreement with Pluri under which ZEO will issue shares equal to 50% of its post-closing outstanding stock, with ZEO's results expected to consolidate into Pluri's financials after a Q4 2026 close.
Key Events · M&A and Partnerships · ZEOX
-
Definitive Partnership With Pluri
ZEO and Pluri Inc. (Nasdaq/TASE: PLUR) signed a definitive strategic agreement to build a U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness and longevity.
-
Pluri to Own 50% of ZEO
ZEO will initially issue shares representing 50% of its issued and outstanding common stock immediately following Closing — roughly half the post-deal share count goes to Pluri, before any warrants.
-
What ZEO Receives
Defined rights to Pluri's manufacturing technology and know-how (Pluri retains its underlying IP), plus exclusive U.S. rights to the CellaV aesthetic product line including future offerings.
-
Consolidation and Governance Terms
After closing, ZEO's financial results are expected to be consolidated into Pluri's statements; the agreement also includes warrants and corporate governance/protective rights for Pluri.
Analysis · ZEOX · Life Sciences
This is a control-changing transaction, not a routine partnership. ZEO will issue shares equal to 50% of its post-closing outstanding common stock to Pluri, and ZEO's results are expected to be consolidated into Pluri's financials afterward — meaning ZEO effectively becomes a Pluri-controlled subsidiary. Existing ZEO holders are diluted by half on the initial issuance, with warrants and protective rights layered on top. In exchange, ZEO gets Pluri's cell-expansion manufacturing technology, exclusive U.S. rights to the CellaV aesthetics line, and a partner with Phase III clinical experience and a 200-plus patent portfolio. Closing is targeted for Q4 2026 and hinges on ancillary agreements, approvals and valuations; no shareholder vote is required from either side.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 45.6% of the 241 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZEOX was trading at $1.44 on OTC in the Life Sciences sector, with a market capitalization of approximately $11.3M. The 52-week trading range was $0.84 to $2.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.